Anar al contingut
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avançada
  • S110: PHALLCON: A PHASE 3 STUD...
  • Citar
  • Enviar aquest missatge de text
  • Enviar per correu electrònic aquest
  • Imprimir
  • Exportar registre
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Enllaç permanent
S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

Dades bibliogràfiques
Autors principals: Elias Jabbour, Hagop Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Leonard, David Gomez, Maria Baer, Carlo Gambacorti-Passerini, James Mccloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice Wang, Meliessa Hennessy, Niti Patel, Alexander Vorog, Bingxia Wang, Huilan Yao, Tammie Yeh, Josep Maria Ribera
Format: Article
Idioma:English
Publicat: Wiley 2023-08-01
Col·lecció:HemaSphere
Accés en línia:http://journals.lww.com/10.1097/01.HS9.0000967352.68516.d0
  • Fons
  • Descripció
  • Ítems similars
  • Visualització del personal

Internet

http://journals.lww.com/10.1097/01.HS9.0000967352.68516.d0

Ítems similars

  • PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
    per: E. Jabbour, et al.
    Publicat: (2022-06-01)
  • Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
    per: David Sanford, et al.
    Publicat: (2015-12-01)
  • The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
    per: Aziz Nazha, et al.
    Publicat: (2013-10-01)
  • Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts
    per: Preetesh Jain, et al.
    Publicat: (2013-11-01)
  • P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
    per: J. Apperley, et al.
    Publicat: (2022-06-01)

Opcions de cerca

  • Historial de cerca
  • Cerca avançada

Trobar-ne més

  • Explorar el catàleg
  • Explorar alfabèticament
  • Explora canals
  • Bibliografia recomanada
  • Nous ítems

Necessites ajuda?

  • Consells de cerca
  • Pregunteu al bibliotecari
  • FAQs